Rx watchdog report: brand name drug prices continue to climb despite low general inflation rate
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Insight on the issues (AARP Public Policy Institute)
- Contributor(s):
- Purvis, Leigh. Schondelmeyer, Stephen W. AARP (Organization) Public Policy Institute (AARP (Organization))
- Publication:
- Washington, D.C. : AARP Public Policy Institute, c2010
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Drug Costs -- trends Prescription Drugs -- economics Drugs, Generic -- economics Forecasting Health Care Reform -- economics Inflation, Economic Medicare Part D -- economics Pharmaceutical Preparations -- economics Humans United States
- Genre(s):
- Technical Report
- Abstract:
- AARP's Public Policy Institute finds that average manufacturer price increases for brand name and specialty prescription drugs widely used by Medicare beneficiaries continued to far outstrip the price increases for other consumer goods and services in the 12 months ending with March 2010. In contrast, average manufacturer prices for widely used generic drugs fell during the same time period. These trends resulted in an average annual rate of increase of 5.3 percent for manufacturer drug prices during the 12 months ending with the first quarter of 2010 despite an extremely low rate of general inflation for all consumer goods and services. This report presents findings from the first quarter of 2010 on the pattern of manufacturer price changes for brand name, specialty, and generic drugs widely used by Medicare Part D beneficiaries.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
- Extent:
- 13 p.
- Illustrations:
- Illustrations
- NLM Unique ID:
- 101535468 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101535468